14TM

14TM is a preclinical-stage biotechnology company focused on discovering next-generation medicines targeting G protein-coupled receptors (GPCRs), specifically focusing on receptor dimers and higher-order oligomers. Launched by Apple Tree Partners (ATP), the company leverages the pioneering structural biology research of founders Bryan Roth and Georgios Skiniotis. By utilizing high-resolution cryo-electron microscopy (cryo-EM) and advanced computational chemistry, 14TM maps the "14-transmembrane" structures formed by GPCR pairs to identify unique, previously inaccessible binding sites. This approach allows for the development of highly selective small molecules designed to treat complex conditions in the central nervous system and metabolic therapeutic areas. The company aims to overcome the limitations of traditional GPCR targeting by exploiting the specific spatial arrangements and signaling profiles of receptor complexes.